Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?

Executive Summary

Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)

You may also be interested in...



Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy

Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products

Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy

Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products

Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy

Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel